Itolizumab was associated with high clinical response rates at Day 15 and 29Responders were able to taper steroids by 70% at Day 29 and 99% at Day 169Itolizumab being evaluated in pivotal Phase 3 EQUATOR study in first-line acute graft-versus-host diseaseLA JOLLA, Calif. (BUSINESS WIRE) $EQ #GVHD Equillium, Inc.
Ryvu Therapeutics Presents Clinical and Translational Data of RVU120 and SEL24 (MEN1703) at the 2022 American Society of Hematology (ASH) Annual Meeting streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ VentureMed Group, Inc., a privately held medical device innovator in access management for arteriovenous (AV) fistulas and grafts and vessel.
FLEX Vessel Prep 12 Month AV Registry Data and 12 Month Belong PAD Data Shows Benefit to Micro-incisions Before Balloon or DCB Treatment streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.